What is the current stock price of Lucid Diagnostics Inc. (LUCD)?

As of the latest market data, Lucid Diagnostics Inc. (LUCD) is trading at $1.15. The stock has seen a loss of 0.00% today.

Does Lucid Diagnostics Inc. (LUCD) pay a dividend?

Based on current data, Lucid Diagnostics Inc. does not have a confirmed active dividend policy.

What is the market cap of Lucid Diagnostics Inc.?

The current market capitalization of Lucid Diagnostics Inc. (LUCD) is approximately unavailable.

LUCD

Lucid Diagnostics Inc.·Healthcare

1.15

0.000%(+0.00)

Market Closed

1.25

8.696%(+0.10)

After Hours

Last Updated: — ET

52W L: $0.9552W H: $1.70

LUCD NEWS

prnewswire.com

1d ago

Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.

prnewswire.com

Apr 2

PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.

prnewswire.com

Mar 30

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submission Lucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM EST NEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and year ended December 31, 2025. Conference Call and Webcast The webcast will take place on Monday, March 30, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.

defenseworld.net

Mar 28

Lucid Diagnostics Q4 Earnings Call Highlights

Lucid Diagnostics (NASDAQ: LUCD) reported higher fourth-quarter 2025 EsoGuard testing volume and revenue and highlighted progress on reimbursement initiatives, including a new U.S. Department of Veterans Affairs (VA) contract and ongoing discussions with Medicare and commercial payers. Fourth-quarter test volume exceeded company's target range Chairman and CEO Dr. Lishan Aklog said fourth-quarter EsoGuard test volume totaled

defenseworld.net

Mar 27

Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus PT from Brokerages

Shares of Lucid Diagnostics Inc. (NASDAQ: LUCD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average

seekingalpha.com

Mar 26

Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

2021-10-14

Beta

1.25

Websitewww.luciddx.com↗